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■ Summary
Drugs with antihistamine action are among the most commonly prescribed medicines in pediatrics. According to the International Medical 
Statistics (IMS), almost two million antihistamine units (in solution) for pediatric use were sold in Spain during 2006 - at a cost of nearly 
6 million euros. Of this amount, 34% corresponded to fi rst-generation (or sedating) antihistamines.
The diffi culties inherent to research for drug development increase considerably when the pediatric age range is involved. The use of any 
medication in this age group must adhere to the strictest safety criteria, and must offer the maximum guarantees of effi cacy. For this reason, 
detailed knowledge of the best scientifi c evidence available in relation to these aspects is essential for warranting drug use.
The fi rst-generation antihistamines have never been adequately studied for pediatric age groups, though they are still widely used in 
application to such patients. In contrast, studies in children have been made with the second-generation antihistamines, allowing us to 
know their safety profi le, and such medicines are available at pediatric dosages that have been well documented from the pharmacological 
perspective.
The present review affords an update to our most recent knowledge on antihistamine use in children, based on the best scientifi c evidence 
available.
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■ Resumen
Los medicamentos con acción antihistamínica son uno de los grupos terapéuticos más usados en pediatría. En España, según datos de 
IMS, se vendieron en 2006 cerca de dos millones de unidades de antihistamínicos (en solución) para uso pediátrico, lo que supuso un 
gasto de casi 6 millones de euros. De este montante un 34% fueron antihistamínicos de primera generación o sedativos.
Las difi cultades propias de la investigación para el desarrollo de fármacos se incrementan mucho cuando se trata de edades pediátricas. 
El uso de cualquier fármaco en este grupo de edades debe argumentarse siguiendo los criterios más estrictos de seguridad y con las 
máximas garantías de efi cacia. Por este motivo, el conocimiento detallado de las mejores pruebas científi cas disponibles en estos aspectos 
es fundamental para respaldar su uso.
Los antihistamínicos de primera generación no han sido nunca correctamente estudiados para los grupos de edades pediátricas y sin 
embargo, siguen siendo muy utilizados. Los antihistamínicos de segunda generación sí han aportado estudios en niños que permiten conocer 
su perfi l de seguridad, y están disponibles en dosifi caciones pediátricas bien documentadas desde el punto de vista farmacológico.
En esta revisión se pretende realizar una actualización del conocimiento más reciente en cuanto al uso de antihistamínicos en niños, a 
través de un enfoque basado en las mejores pruebas científi cas disponibles.
Palabras clave: Antihistamínicos. Pediatría. Niños. Rinitis alérgica. Dermatitis atópica. Conjuntivitis alérgica.
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Introduction
Drugs with antihistamine action are among the most 
commonly prescribed medicines in pediatrics. According to the 
data obtained by the Alergológica 2005 study [1], of the Spanish 
Society of Allergology and Clinical Immunology, 56.4% of all 
pediatric patients (under age 14 years) in the study had received 
some antihistamine prior to visiting the allergologist. Of these 
drugs, 22% corresponded to fi rst-generation antihistamines. 
According to the International Medical Statistics (IMS), almost 
two million antihistamine units (in solution) for pediatric use 
were sold in Spain during 2006 - at a cost of nearly 6 million 
euros. Of this amount, 34% corresponded to fi rst-generation 
(or sedating) antihistamines.
The diffi culties inherent to research for drug development 
increase considerably when the pediatric age range is 
involved. The use of any medication in this age group must 
adhere to the strictest safety criteria, and must offer the 
maximum guarantees of effi cacy. For this reason, detailed 
knowledge of the best scientifi c evidence available in relation 
to these aspects is essential for warranting drug use.
The European Medicines Evaluation Agency (EMEA), 
in its document “Guide to the clinical development of 
medical products for the treatment of rhinoconjunctivitis”, 
under the section on special considerations in pediatric 
patients, specifi es that in children over two years of age the 
pharmacokinetic studies made prior to drug authorization 
suffi ce to establish the minimum effective dose - assuming 
that the effi cacy results in adolescents /adults are also valid for 
children. For children under two years of age, where immune 
reaction is considered to be different, specifi c effi cacy studies 
are required. In all the age groups the safety data are of greater 
importance, and studies involving one to three months of 
follow-up are demanded, with special attention to the adverse 
effects upon growth. 
The first-generation antihistamines have never been 
adequately studied for pediatric age groups, though they are 
still used in an apparently high percentage of such patients. In 
contrast, studies in children have been made with the second-
generation antihistamines, allowing us to know their safety 
profi le, and such medicines are available at pediatric dosages 
that have been well documented from the pharmacological 
perspective.
Over fi ve years have elapsed since the last exhaustive 
review based on scientifi c evidence was published in relation 
to antihistamine use in pediatrics [2], and since then new data 
have appeared and new scientifi c contributions have been 
made that allow us to amplify current knowledge in support 
of antihistamine use in pediatric patients. The present review 
affords an update to such knowledge on antihistamine use in 
children, based on the best scientifi c evidence available.
Pharmacological aspects of 
antihistamines in pediatrics
The drug pharmacokinetic and pharmacodynamic 
characteristics can differ greatly depending on the age 
group considered. These characteristics determine effi cacy 
and particularly safety, and make it possible to predict the 
behavior of a given drug in the body.
Table 1 shows the most important pharmacological aspects 
according to the studies published on the antihistamines most 
widely used in pediatrics [3-23].
In general, antihistamines are well absorbed following 
oral administration as both solid and liquid formulations, and 
reach maximum plasma concentrations between 1-4 hours 
after dosing in both pediatric patients and in adults.
The plasma half-life depends on the drug metabolization 
and clearance processes within the body, and although such 
processes are the same in both children and in adults, they are 
comparatively accelerated in children in the case of certain 
antihistamines. As a result, ideal dosing in such cases is once 
every 12 hours instead of once every 24 hours (e.g., in the 
case of levocetirizine in kindergarten children) [18-20].
All fi rst-generation antihistamines, as well as most second-
generation drugs, are metabolized in the liver by the P450 
cytochrome enzyme system. Only cetirizine, levocetirizine 
and fexofenadine are largely eliminated without metabolic 
transformation (in urine in the fi rst two cases, and in bile in 
the case of fexofenadine).
There are no studies of the effects of possible drug 
interactions in pediatric age groups between antihistamines 
and P450 cytochrome inhibitors, or drugs which are 
metabolized via this pathway. The only exception is a study of 
children with chloroquine-resistant malaria, where the plasma 
concentrations of this drug were seen to be signifi cantly 
greater, and were reached sooner, when administered in 
combination with chlorpheniramine [23].
The pharmacodynamic aspects, such as the onset of action 
and its duration, are studied both in children and in adults 
based on the histamine-induced skin wheal and erythema 
inhibition model. The last column in Table 1 reports the time 
intervals in which signifi cant wheal and erythema inhibition 
takes place with the different antihistamines. For most of 
them, the time to action is within one hour, with persistence 
of the effect during 24 hours.
In the same way as in adults, no tachyphylaxis or tolerance 
of this effect on histamine-induced wheal and erythema 
production is observed [8].
Effi cacy of antihistamines in the 
treatment of allergic rhinitis in children
Allergic rhinitis (hay fever) is the most frequent chronic 
disorder in the pediatric population, and its prevalence is 
increasing [24]. It can have an important impact upon the 
health of the child, causing a reduction in quality of life [25], 
and can infl uence the development of associated diseases such 
as asthma, sinusitis or seromucosal otitis [26].
The H1 antihistamines have demonstrated their effi cacy in 
the treatment of pediatric allergic rhinitis in many studies and 
in different age groups, though the methodological quality 
of such studies has increased considerably only in the last 
two decades. There are no well conducted clinical studies in 
children involving fi rst-generation antihistamines; as a result, 
the latter should not be recommended as fi rst line treatment. 
29
A del Cuvillo, et al




















































































































































































































































































































































































































































































































































































































































































































































Use of antihistamines in pediatrics
 J Investig Allergol Clin Immunol 2007; Vol. 17, Suppl. 2: 28-40© 2007 Esmon Publicidad
corticoids for improving nasal congestion or the rest of 
symptoms of allergic rhinitis in children - in contrast to the 
situation in adults, where such studies have been made.
Effi cacy of antihistamines in the 
treatment of childhood asthma
A recent epidemiological study conducted in Spain, 
Alergológica 2005 [1], showed that in children under 14 
years of age with bronchial asthma, antihistamine treatment 
was indicated in up to 30% of cases.
Histamine is an important infl ammatory mediator within 
the respiratory tract. Following provocation by an inhaled 
allergen, it has been demonstrated that plasma histamine 
levels increase, coinciding with the immediate and late 
response phases of the allergic reaction. A rise in plasma 
histamine also has been reported during asthma attacks.
However, there is suffi cient scientifi c evidence to recommend 
the use of second-generation antihistamines in the different 
pediatric age groups: cetirizine, levocetirizine, ebastine, 
fexofenadine and loratadine all have well documented clinical 
effi cacy in children - particularly after four years of age [2,27-
31]. For younger patients, studies are made fundamentally 
to assess safety, and less information is obtained on effi cacy 
- due to the diffi culty of conducting randomized, controlled 
and masked clinical trials in small children. Adults show a 
strong placebo effect in clinical studies of allergic rhinitis. In 
children, this placebo effect may be a comparatively stronger 
confounding factor, particularly when effi cacy assessment is 
based on subjective parameters such as symptoms scores or 
days without symptoms (Figure 1). To avoid this problem, 
it would be advisable to base such studies on objective 
measures of improvement such as infl ammatory markers 
(nasal nitric oxide, nasal cytology) or the measurement 
of nasal peak inspiratory fl ow, in order to establish dose-
response correlations.
In recent years, health-related quality of life (HRQoL) 
has become a very important clinical variable for assessing 
drug effi cacy, based on the use of adequately validated 
generic or specifi c questionnaires. We now have studies with 
solid methodological designs that assess the usefulness of 
antihistamines in improving the quality of life of children 
with allergic rhinitis (Figure 2) [29].
In the same way as in adults, antihistamines are 
effective in alleviating most of the symptoms of pediatric 
allergic rhinitis: itching, rhinorrhea, and sneezing - though 
they appear to be less effective against nasal congestion. 
There are no randomized, controlled and masked clinical 
trials warranting the use of formulations that mix fi rst-
generation antihistamines with nasal decongesting agents 
(systemic vasoconstrictors), despite the fact that they are 
so often used in pediatric practice. A clinical study [32] has 
demonstrated the effi cacy (in terms of symptoms reduction) 
of loratadine (a second-generation antihistamine) combined 
with pseudoephedrine.
Likewise, no clinical studies have been published 




























Figure 2. Taken from reference 29. 
Improvement in the score of the Juniper 
pediatric quality of life questionnaire 
(PRQLQ) in a series of 306 children 
between 6-12 years of age randomized 
to receive levocetirizine or placebo as 
treatment for allergic rhinitis during four 
weeks, with double-blind masking.
Figure 1. Taken from reference 32. In this placebo controlled and masked 
study, both the placebo group and the active treatment group showed 
signifi cant differences in total symptoms score versus baseline - though in 
the active treatment series the total score was signifi cantly more reduced 
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Antihistamines such as ketotifen, cetirizine and loratadine 
have shown a range of effects upon asthma: they reduce 
exercise-induced asthma attacks [33], improve cough in 
children with pollen allergy during the pollinic season [34], 
and improve asthma symptoms in children [35].
A systematic review with metaanalysis has been 
published on the effi cacy of ketotifen as treatment alone or 
in combination with other drugs for the control of asthma 
and wheezing in children [36]. The review concluded that 
the scientifi c evidence derived from randomized controlled 
trials indicates that ketotifen alone or in combination with 
other co-interventions effectively improves asthma and 
wheezing control in children with mild and moderate asthma. 
However, due to the high proportion of atopic children in 
some trials, the results are not necessarily extendable to all 
asthmatic children. The cost of the resulting benefi t comprises 
minor side effects such as sedation and body weight gain. 
The validity of this conclusion is limited by the defi cient 
methodological quality of the trials included in the review.
According to the fi ndings of the epidemiological study, 
Alergológica 2005 [1], a full 51.6% of the asthmatic children 
included (under 14 years of age) suffered allergic rhinitis-
conjunctivitis - thus supporting the hypothesis that rhinitis 
and asthma form part of one same disease, on the basis 
of their binding characteristics: histological (respiratory 
epithelium), physiological (nasobronchial reflex), and 
pathological (immune response to aeroallergens in two phases 
- immediate and late). In many cases, asthmatic patients 
with rhinitis receive antihistamine treatment, and it has been 
seen that in such situations patient lung function improves 
signifi cantly [37]. Likewise, scientifi c evidence indicates that 
correct management of rhinitis is associated with a signifi cant 
reduction in the risk of hospital admission and/or emergency 
care due to asthma attacks [38].
Many studies have shown allergic rhinitis to be an 
independent risk factor for the development of asthma [39]. 
It is interesting to postulate whether correct treatment of 
rhinitis using antihistamines may prevent the development 
of asthma, or even whether the treatment of atopic dermatitis 
with antihistamines is able to prevent the disease. A number of 
clinical studies have attempted to demonstrate this possibility 
for ketotifen, cetirizine and loratadine - concluding that 
ketotifen is very useful for preventing the development of 
asthma in children with atopic dermatitis and high IgE levels 
[40]. In addition, ketotifen has been shown to be effective 
in preventing the development of asthma in children with 
a family history of respiratory allergy and high IgE levels 
[41], and cetirizine prevents the development of asthma in 
children with atopic dermatitis sensitized to aeroallergens. 
Moreover, such preventive effects persist for 18 months 
after discontinuing the treatment (Figure 3) [42]. In turn, 
loratadine has been shown to reduce the number of respiratory 
exacerbations during the treatment period in a group of 
children with repeated ear, nose and throat infections (5 or 
more), without prior asthma [43].
A metaanalysis has reviewed the effi cacy of oxatomide 
in relation to stable asthma control in adults and children. 
The study concluded that there is no scientifi c evidence that 
this drug exerts a signifi cant effect upon the control of stable 
asthmatic disease - though a number of studies reported 
benefi ts in terms of subjective parameters. The adverse effects 
were greater with oxatomide than with placebo [44].
Effi cacy of antihistamines in the 
treatment of atopic dermatitis in 
children
The Alergológica 2005 epidemiological study [1] showed 
that 73.6% of the children diagnosed with atopic dermatitis and 
included in the study were prescribed antihistamine therapy - a 
fi rst-generation drug being involved in 20% of the cases.
The physiopathology of atopic dermatitis is complex and 
involves multiple cell populations, which in turn produce a 
range of cytokines and chemokines that interact with each 
other. One feature is the presence of mast cells within the 
papillary and reticular dermis of the affected skin areas, where 
histamine appears to play a role as cofactor in itching.
Antihistamines are widely used to treat this disease, 
despite the fact that there are no clinical studies of suffi cient 
methodological quality to warrant such generalized practice. 
A metaanalysis has reviewed the existing scientifi c evidence 
on the effi cacy of antihistamines in reducing pruritus due 
to atopic dermatitis. The conclusion was that there is scant 
objective evidence of any relief of this symptom, and that 
antihistamine effi cacy in application to atopic dermatitis 
remains to be demonstrated [45]. As an anecdote, this 
metaanalysis mentions that the sedating antihistamines 
have been found to be useful in some studies, thanks to their 
capacity to induce drowsiness or sedation. However, there 
is one study that has concluded that chlorpheniramine is not 
more effective than placebo in ameliorating the symptoms of 
childhood atopic dermatitis with nocturnal itching and scratch 
marks, and that antihistamine use does not affect the amount 
of topical treatment used over the short term [46].
In a clinical study published after the aforementioned 
metaanalysis, it was concluded that cetirizine reduces the 
Figure 3. Taken from reference 42. Probability of developing asthma in 
children according to treatment with placebo or cetirizine, and according 
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duration and amount of topical corticoid treatment used in 
children with the worst atopic dermatitis (according to the 
SCORAD index) [47].
Effi cacy of antihistamines in the 
treatment of childhood urticaria
 Acute urticaria is the most common type of urticaria in the 
pediatric population, and is normally caused by an immediate 
hypersensitivity reaction to some food, or following viral 
infections. Chronic urticaria is much less common in children, 
and an important percentage of diagnosed cases correspond 
to physical causes [1,48].
The Alergológica 2005 epidemiological study [1] showed 
82.3% of the cases of urticaria in children under 14 years of age 
included in the study were of an acute nature, while the remaining 
17.7% of cases were diagnosed as chronic presentations [1].
In adults, the H1 antihistamines have demonstrated their 
effi cacy in alleviating urticaria symptoms, though to date 
no studies of the required methodological quality have been 
conducted in children with urticaria of any origin.
In another study carried out in children presenting 
atopic dermatitis, and involving cetirizine administered 
with the purpose of preventing the development of asthma, 
a prophylactic effect was demonstrated in relation to acute 
urticaria, since during the 18 months of active treatment the 
number of acute urticaria episodes was signifi cantly lower 
than in the placebo series - an effect that did not persist during 
18 months of follow-up without active treatment [49].
Effi cacy of antihistamines in the 
treatment of anaphylaxis in children
Few data have been published on the role of antihistamines 
in the treatment of anaphylaxis in children.
A study has assessed the role of promethazine in the 
prevention of anaphylaxis following the bite of a type of 
snake found in tropical South America (mapanare) - no 
signifi cant performance in favor of the active treatment group 
versus placebo being found [50].
In a review of 22 cases of idiopathic anaphylaxis in 
children, treatment including hydroxyzine and in some cases 
ketotifen proved successful in improving patient response to 
corticoids. Intramuscular adrenalin was always on hand for 
immediate treatment, and the antihistamine was used as an 
adjuvant for symptoms control [51].
Effi cacy of antihistamines in the 
treatment of respiratory tract 
infections in children
Formulations containing antihistamines only, or in 
combination with other drugs (antitussive agents, systemic 
decongesting drugs, etc.), are widely used for symptoms 
control and the treatment of respiratory tract infections in 
children.
A metaanalysis has reviewed the usefulness of 
antihistamine treatment in application to the common cold, 
concluding that these drugs administered as monotherapy 
in adults and children afford no clinical relief of nasal 
congestion, rhinorrhea or sneezing, and do not subjectively 
improve the common cold. Moreover, the fi rst-generation 
antihistamines induced more side effects than placebo, 
particularly increased sedation in the patients with a common 
cold. The combinations of antihistamines with decongesting 
agents are not effective in small children. In older children 
and in adults, most studies report a benefi cial effect in terms 
of general recovery, as well as in the nasal symptoms, when 
these combinations are used. However, the metaanalysis also 
concludes that the clinical relevance of these effects is not 
clear (Figure 4) [52].
In another study designed to determine whether continued 
treatment with a non-sedating antihistamine (loratadine) 
is able to prevent upper airways infections, the only 
conclusion was that children administered the drug suffered 
fewer respiratory exacerbations during the active treatment 
phase than the placebo group - though this protective effect 
disappeared on suspending the treatment [43]. This study 
concluded that the upper airways infections rate in children 
at risk of suffering such infections decreases considerably 
with age, and is not signifi cantly infl uenced by treatment 
with loratadine.
Effi cacy of antihistamines in the 
treatment of otitis media in children
Otitis media is the most common cause of childhood 
hearing loss, and is one of the most common reasons for 
visiting the pediatrician [53]. Elevations in histamine 
concentration in the middle ear effusions of patients with 
otitis media have been demonstrated [54], along with 
elevations in other allergic infl ammation mediators. The use 
of antihistamines in application to this pathology therefore 
could be justifi ed.
A metaanalysis has reviewed the effi cacy of antihistamines 
either alone or in combination with decongesting agents, in 
the treatment of otitis media with effusion (seromucosal 
otitis). No statistically or clinically signifi cant benefi t was 
observed in relation to any of the interventions or results 
considered. Nevertheless, the treated subjects suffered an 11% 
greater incidence of side effects than the non-treated patients. 
The calculated number-needed-to-treat (NNT) to cause an 
adverse effect was found to be 9. The authors of the study 
therefore recommended that such therapy should be avoided. 
As regards the research implications, this systematic review 
concluded that antihistamines may be useful specifi cally for 
seromucosal otitis in allergic patients [55].
Another metaanalysis has reviewed the effect of 
antihistamines (and of nasal decongestants) in application 
to acute otitis media in children. The study concluded 
that only the group administered active treatment with 
the combination of both types of drug showed clinically 
signifi cant improvement - though the benefi t in any case 
was small, and the study design may have biased the results. 
A del Cuvillo, et al
J Investig Allergol Clin Immunol 2007; Vol. 17, Suppl. 2: 28-40 © 2007 Esmon Publicidad
which tends to accompany rhinitis - since many studies 
designed to assess antihistamine effi cacy in rhinitis included 
some variable for assessing the effect of treatment upon 
conjunctivitis.
Topical ketotifen applied to the eye is able to signifi cantly 
reduce ocular itching after conjunctival provocation with the 
causal allergen [59].
Emedastine and levocabastine in ophthalmological 
solution have been shown to alleviate the symptoms of 
allergic conjunctivitis in children - symptoms reduction being 
signifi cantly greater with emedastine than with levocabastine 
[60].
A study made with azelastine in eyedrops showed this 
topical solution to signifi cantly reduce the symptoms of 
nonspecifi c conjunctival hyper-responsiveness in children 
with allergy to dust mites who presented this syndrome [61]. 
Likewise, azelastine was seen in another study to signifi cantly 
reduce the symptoms scores in small children with seasonal 
allergic conjunctivitis, compared with placebo [62].
A study has also been published comparing the effi cacy 
of levocabastine versus sodium cromoglycate (both as topical 
ophthalmological formulation) for the control of symptoms 
of seasonal allergic conjunctivitis when used upon demand 
versus continuous nasal spray treatment. Both treatment 
modalities were found to be equally effective, though the 
investigators concluded that for certain symptoms such as 
sneezing, lacrimation and nasal congestion, levocabastine 
was signifi cantly better than sodium cromoglycate in reducing 
such manifestations [63].
3. Other uses without indication
Studies have been published that demonstrate the effi cacy 
of antihistamines in relation to indications not contemplated 
in the Summary of Product Characteristics. Examples include 
loratadine for the prevention of mosquito bite reactions in 
sensitive children [64], the itching of varicella [65], ketotifen 
The observed risk of adverse events was 5- to 8-fold greater 
among the active treatment patients than in the placebo series, 
and this difference proved signifi cant for the groups receiving 
treatment with decongesting agents [56].
Other uses of antihistamines in children
1. Antihistamine effi cacy in application to cough
A metaanalysis reviewing antihistamine effectiveness 
in the treatment of prolonged nonspecifi c cough in children 
concluded that on the basis of the existing scientifi c evidence, 
empirical treatment with these drugs cannot be recommended 
- in contraposition to the recommendations in adults. The 
analysis also stressed that the systematic review posed 
important limitations, since only three studies with marked 
methodological differences could be included. It was thus 
concluded that if antihistamine treatment is decided, it 
should be discontinued if no response is elicited within two 
weeks [57].
Another metaanalysis evaluated the efficacy of 
antihistamines in acute cough in children - concluding 
that antihistamines in combination with decongestants 
( b r o m p h e n i r a m i n e / p h e n y l p r o p a n o l a m i n e  a n d 
brompheniramine/phenylephrine/propanolamine) was no 
superior to placebo in the two studies included, and that 
antihistamines alone (clemastine and chlorpheniramine) 
afforded no greater benefi t than placebo in another study 
[58].
2. Antihistamine effi cacy in application to allergic 
conjunctivitis
Although few studies unequivocally and independently 
document the effi cacy of antihistamines in application to 
allergic conjunctivitis, there are suffi cient to date to indicate 
that antihistamines are effective in treating this disorder, 
Journal:  Antihistamines for the common cold  
Comparison: 01 monotherapy - general evaluation - all trials 
Consequence: 01 at short term (1-2 days)   
Study    Treatment     Controls    Peto disparity ratio   Weighting  Peto disparity ratio
     n/N   n/N   95%    (%)    95% CI
                      
      Cowan 1950    283 / 388  139 / 207       13.9 1.32.[0.91, 1.92]
      Henauer 1988     11 / 28    21 / 35        2.0 0.44 [0.17, 1.19]
      Howard 1979      97 / 133  112 / 138        6.0 0.63 [0.36, 1.11]
      Lorriman 1950         306 / 697  286 / 710      42.6 1.16 [0.94, 1.43]
      MRC (Parte II) 1950        301 / 579  334 / 577      35.6 0.79 [0.63, 0.99]
Total (95 % IC)    998 /1825 892 / 1667             100.0 0.97 [0.85, 1.12]
Chi-square heterogeneity test=13.22 gl=4 p=0.0103
General effect test Z= 0.37 p=0.7
-1 2 1 6 10
Supports treatment       Supports control
Figure 4. Taken from reference 52. Metaanalysis of the effi cacy of antihistamines in alleviating the symptoms of the common cold (general evaluation), 
over the short term.
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in ulcerative colitis [66], cetirizine in eosinophilic cellulitis 
[67], as premedication in anesthesia [68-70], the treatment 
of nausea and vomiting caused by antineoplastic treatment 
in children [71], or for reinforcing chloroquine treatment in 
children with malaria [72].
Role of antihistamines as 
antiinfl ammatory medication in 
children
The effi cacy of antihistamines is attributed mainly to their 
antagonistic effect upon the histamine receptors. We now 
know that these receptors exhibit constitutive spontaneous 
activity, and that the antihistamines act as reverse agonists 
upon them - inactivating the activated conformation and 
reducing the mentioned constitutive activity. The H1 receptor 
has been associated with many actions in relation to allergic 
infl ammation, such as rhinorrhea, smooth muscle contraction, 
and many forms of itching (pruritus). This is mediated by 
the transduction of extracellular signals through G protein 
and intracellular second messengers (inositol triphosphate, 
diacylglycerol, phospholipase D and A2, and increases in 
intracellular calcium concentration). Recently there have also 
been reports of NF-κB transcription factor activation by the H1 
receptors, which would explain the antiinfl ammatory actions of 
antihistamines via this route – since the mentioned transcription 
factor is associated with actions such as the regulation of 
adhesion molecules, chemotaxis, proinfl ammatory cytokine 
production, and antigen presentation [73].
A number of clinical studies in children have shown 
that cetirizine reduces leukotriene production in vitro [74], 
reduces nitric oxide (NO) production [75] and the presence 
of ICAM-1 at endothelial cell membrane level [76], induces 
a change in Th1/Th2 balance in favor of a Th1 response, 
with increases in IFN-gamma and IL-10 [77], and reduces 
cytokines and infl ammatory cell infi ltrates [78].
Ketotifen, in a clinical study versus montelukast, was 
seen to reduce plasma cytokines to a greater extent than 
montelukast, in children with persistent mild asthma [79].
Antihistamines have demonstrated antiinflammatory 
effects in clinical studies in children, both ex vivo and in vivo. 
The true relevance of this antiinfl ammatory action in relation 
to the clinical effect of antihistamine treatment remains to 
be established. 
One of the most important questions in this context is 
the relevance of prescribing antihistamine treatment on an 
intermittent or continuous basis with the purpose of preventing 
the development of disease in asymptomatic subjects presumed 
to present a persistent minimal inflammatory process. A 
recent clinical study has explored this aspect, administering 
desloratadine on an intermittent basis (upon demand) or 
regularly in children diagnosed with allergic rhinitis secondary 
to pollen sensitization. The study concluded that both treatment 
regimens are equally effective in terms of rhinitis control, 
but that regular administration afforded better control of the 
symptoms of bronchial hyper-responsiveness, with a lesser 
use of bronchodilators upon demand, and with better results 
in the methacholine provocation tests [80].
Adverse effects and safety issues of 
antihistamine use in children
The different national and international drug agencies 
admit that there are currently many medicines authorized for 
use in children that have never been adequately investigated 
for application in such patients - though in their day they 
received authorization out of a lack of regulation of the 
required specifi cations. In this sense, their use is still allowed 
because the pharmacovigilance systems have not detected any 
adverse effects requiring their withdrawal from the market. 
Many of the antihistamine indications in children have been 
based on the extrapolation of the effects of these drugs in 
adults. Worse still, calculation of the pediatric doses has been 
done with little or no pharmacokinetic data corresponding to 
the different pediatric age groups.
1. First-generation antihistamines
The fi rst-generation antihistamines extensively cross the 
blood-brain barrier, and therefore exert an important effect 
upon the central nervous system. Few studies have explicitly 
investigated the effect of fi rst-generation antihistamines upon 
the central nervous system in children, though some data have 
been obtained from comparative studies contrasting fi rst- and 
second-generation antihistamines. 
The fi rst-generation antihistamines, diphenhydramine 
and hydroxyzine, were objectively assessed for effects upon 
cognitive processes - P300 potential latency - and drowsiness 
using a visual analog scale (VAS), in children with allergic 
rhinitis. The study concluded that both drugs induce objective 
dysfunction at central nervous system level, and drowsiness 
[81].
Another cl inical  tr ial  evaluated the action of 
chlorpheniramine, terfenadine and placebo upon the central 
nervous system in a group of children with allergic rhinitis 
- concluding that neither terfenadine nor placebo induced 
cognitive changes, in contrast to chlorpheniramine [82].
In another study of 24 children between 7 and 14 years 
of age diagnosed with allergic rhinitis, it was seen that both 
chlorpheniramine and cetirizine induces signifi cant cognitive 
alterations versus placebo, though such alterations were not 
correlated to subjective appraisal of dysfunction as assessed 
by means of a visual analog scale [83].
In addition to the effects upon the central nervous system, 
the fi rst-generation antihistamines - as a result of their action 
upon receptors other than the histamine receptors - can 
cause adverse effects (as has been reported in the literature) 
including vision alterations, mucosal membrane dryness 
and other effects derived from the anticholinergic action of 
these drugs.
As a result of their action upon the serotoninergic 
receptors, some antihistamines can induce an increase in 
appetite and body weight gain. In the case of cyproheptadine, 
this particular effect has been known for a long time (initially 
reported in 1962), and is presently used as a therapeutic 
indication [84,85].
There have been reports of many rare adverse effects 
in children administered fi rst-generation antihistamines, 
including spasms [86], seizures [87], aggressivity [88], 
respiratory distress [89], fixed skin rash [90], central 
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anticholinergic syndrome [91,92] and toxic encephalopathy 
in patients with skin syndromes (atopic dermatitis, varicella) 
involving damage to the skin barrier, in whom fi rst-generation 
antihistamines were applied topically [93].
It is important to consider the consequences of either 
accidental or intentional overdose of these drugs in children. 
As a result of their action upon different types of receptors 
(histaminic, serotoninergic, cholinergic, dopaminergic), the 
fi rst-generation antihistamines are potentially lethal in cases 
of overdose, and both deaths and serious toxicity have been 
documented in pediatric patients [94,95].
2. Second-generation antihistamines
The second-generation antihistamines are known as 
non-sedating antihistamines because they do not cross the 
blood-brain barrier - a fact that minimizes their action upon 
the central nervous system.
Their few adverse effects and good tolerance have 
been well documented in many clinical studies, involving 
administration over long periods of time, and in almost 
all pediatric age groups [2]. Thus, cetirizine [27,96], 
levocetirizine [28,29], loratadine [17,30], desloratadine 
[97,98], ebastine [99] and fexofenadine [31] all have well 
documented safety over the short and middle term, and some 
also over the long term.
An important point arising from antihistamine action 
upon the central nervous system is how such actions can 
affect school performance. Since allergic rhinitis itself is 
able to affect school performance, because of the symptoms 
involved and the impairment of sleep quality, it is important 
to assess the impact of treatment and its adverse effects in 
relation to the disease and to improvement or worsening of 
school performance. A clinical study comparing loratadine 
and diphenhydramine concluded that loratadine improved 
academic performance, in contrast to diphenhydramine, 
which worsened it [100]. Another study evaluated the impact 
of long-term cetirizine treatment in children with atopic 
dermatitis - concluding that there were no adverse effects 
upon learning [101].
A very important issue emerged in the nineties when cardiac 
adverse effects were reported (arrhythmias) in relation to 
second-generation antihistamine use. It has been demonstrated 
that such effects are not class effects but rather are related to each 
particular molecule [73], and there have been reports in children 
of syncope during or after exercise, loss of consciousness or 
palpitations [102] with the administration of astemizole. Both 
this latter drug and terfenadine have been removed from the 
market in the great majority of countries because of this effect, 
and the new antihistamines are required to pass strict safety 
controls in relation to potential cardiotoxicity, before being 
authorized for introduction on the market.
The absence of cardiotoxicity with antihistamines such 
as cetirizine [103], loratadine [103], fexofenadine [104] 
and ebastine [105] has been well established. Since they 
have been marketed only recently, both levocetirizine and 
desloratadine have been required to document the absence of 
such cardiotoxicity according to very strict criteria, based on 
the new demands of the international drug agencies, in order to 
be authorized for use in pediatric patients - though no published 
studies are available.
To date, the pharmacovigilance systems have received no 
reports of arrhythmias related to administration of the rest of 
the second-generation antihistamines at both therapeutic doses 
and in cases of overdose.
 
Conclusions
In the last two decades many clinical studies of suffi cient 
methodological quality have been made and published - thus 
allowing consolidation of the indication for the application of 
second-generation antihistamines to allergic rhinitis in children. 
Although the level of scientifi c support of the use of antihistamines 
for the treatment of mild to moderate asthma, fundamentally in 
relation to ketotifen, is limited by the questionable quality of the 
studies published and analyzed in the context of metaanalyses, 
the use of this antihistamine nevertheless can be recommended. 
In dermatological alterations such as atopic dermatitis or chronic 
urticaria, the indication remains to be established. In some cases, 
and despite the widespread prescription of antihistamines, the 
existing scientifi c evidence advises against their use - as in the 
common cold, seromucosal otitis, or nonspecifi c cough.
Special caution is required when establishing indications 
not contained in the Summary of Product Characteristics, or 
which have not been investigated in the drug development 
phase or expressly in the postmarketing period (such as 
sedation, analgesia or the prevention of vomiting), since 
the potential adverse effects - particularly with the fi rst-
generation antihistamines - make the safety of such practices 
questionable to say the least.
It also must be commented that many of these fi rst-
generation antihistamines, with authorization in the Summary 
of Product Characteristics for pediatric use, are over-the-
counter (OTC) drugs freely available in pharmacies - a fact 
that adds to the potential for adverse effects.
Table 2 reports the degree of recommendation and the 
levels of scientifi c evidence according to the classifi cation 
of Shekelle et al. [106], based on the publications considered 
in this review.
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Table 2. Evidence in support of antihistamine use in different 
pathologies
Clinical picture Degree of evidence
 (Level of recommendation)
Allergic rhinoconjunctivitis 1b (A)
Asthma (only ketotifen) 1a (A) 
Atopic dermatitis 2b (B)
Urticaria  1b (A)
Anaphylaxis 3 (C)
Respiratory infections * 4 (D)
Otitis media * 4 (D)
* The existing evidence advises against use in these clinical conditions, 
due to the risk of adverse effects
Use of antihistamines in pediatrics
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In conclusion, and on the basis of the present review, 
it seems clear that the non-cardiotoxic second-generation 
antihistamines are the drugs of choice for the recommended 
treatment indications, for patients of all ages. In this context, 
the fi rst-generation drugs should be held in reserve for 
infrequent situations where their adverse effects may prove 
desirable, or when parenteral dosing is required.
It appears necessary to continue focusing research 
on concrete population subgroups or specifi c indications 
(seromucosal otitis, asthma in allergic children, etc.), in order 
to warrant these indications and further defi ne aspects such 
as the dosage and the treatment regimen best suited to each 
individual case.
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